View in EDS HTML Full Text PDF Full Text

European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment.

Saved in:
Bibliographic Details
Title: European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment.
Authors: Roessner, Veit, Eichele, Heike, Stern, Jeremy S., Skov, Liselotte, Rizzo, Renata, Debes, Nanette Mol, Nagy, Péter, Cavanna, Andrea E., Termine, Cristiano, Ganos, Christos, Münchau, Alexander, Szejko, Natalia, Cath, Danielle, Müller-Vahl, Kirsten R., Verdellen, Cara, Hartmann, Andreas, Rothenberger, Aribert, Hoekstra, Pieter J., Plessen, Kerstin J.
Source: European Child & Adolescent Psychiatry. Mar2022, Vol. 31 Issue 3, p425-441. 17p. 1 Chart, 2 Graphs.
Subjects: Aripiprazole, Tourette syndrome, Tic disorders, Dopamine antagonists, Risperidone
Abstract: In 2011, the European Society for the Study of Tourette Syndrome (ESSTS) published the first European guidelines for Tourette Syndrome (TS). We now present an update of the part on pharmacological treatment, based on a review of new literature with special attention to other evidence-based guidelines, meta-analyses, and randomized double-blinded studies. Moreover, our revision took into consideration results of a recent survey on treatment preferences conducted among ESSTS experts. The first preference should be given to psychoeducation and to behavioral approaches, as it strengthens the patients' self-regulatory control and thus his/her autonomy. Because behavioral approaches are not effective, available, or feasible in all patients, in a substantial number of patients pharmacological treatment is indicated, alone or in combination with behavioral therapy. The largest amount of evidence supports the use of dopamine blocking agents, preferably aripiprazole because of a more favorable profile of adverse events than first- and second-generation antipsychotics. Other agents that can be considered include tiapride, risperidone, and especially in case of co-existing attention deficit hyperactivity disorder (ADHD), clonidine and guanfacine. This view is supported by the results of our survey on medication preference among members of ESSTS, in which aripiprazole was indicated as the drug of first choice both in children and adults. In treatment resistant cases, treatment with agents with either a limited evidence base or risk of extrapyramidal adverse effects might be considered, including pimozide, haloperidol, topiramate, cannabis-based agents, and botulinum toxin injections. Overall, treatment of TS should be individualized, and decisions based on the patient's needs and preferences, presence of co-existing conditions, latest scientific findings as well as on the physician's preferences, experience, and local regulatory requirements. [ABSTRACT FROM AUTHOR]
Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 155911938
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Roessner%2C+Veit%22">Roessner, Veit</searchLink><br /><searchLink fieldCode="AR" term="%22Eichele%2C+Heike%22">Eichele, Heike</searchLink><br /><searchLink fieldCode="AR" term="%22Stern%2C+Jeremy+S%2E%22">Stern, Jeremy S.</searchLink><br /><searchLink fieldCode="AR" term="%22Skov%2C+Liselotte%22">Skov, Liselotte</searchLink><br /><searchLink fieldCode="AR" term="%22Rizzo%2C+Renata%22">Rizzo, Renata</searchLink><br /><searchLink fieldCode="AR" term="%22Debes%2C+Nanette+Mol%22">Debes, Nanette Mol</searchLink><br /><searchLink fieldCode="AR" term="%22Nagy%2C+Péter%22">Nagy, Péter</searchLink><br /><searchLink fieldCode="AR" term="%22Cavanna%2C+Andrea+E%2E%22">Cavanna, Andrea E.</searchLink><br /><searchLink fieldCode="AR" term="%22Termine%2C+Cristiano%22">Termine, Cristiano</searchLink><br /><searchLink fieldCode="AR" term="%22Ganos%2C+Christos%22">Ganos, Christos</searchLink><br /><searchLink fieldCode="AR" term="%22Münchau%2C+Alexander%22">Münchau, Alexander</searchLink><br /><searchLink fieldCode="AR" term="%22Szejko%2C+Natalia%22">Szejko, Natalia</searchLink><br /><searchLink fieldCode="AR" term="%22Cath%2C+Danielle%22">Cath, Danielle</searchLink><br /><searchLink fieldCode="AR" term="%22Müller-Vahl%2C+Kirsten+R%2E%22">Müller-Vahl, Kirsten R.</searchLink><br /><searchLink fieldCode="AR" term="%22Verdellen%2C+Cara%22">Verdellen, Cara</searchLink><br /><searchLink fieldCode="AR" term="%22Hartmann%2C+Andreas%22">Hartmann, Andreas</searchLink><br /><searchLink fieldCode="AR" term="%22Rothenberger%2C+Aribert%22">Rothenberger, Aribert</searchLink><br /><searchLink fieldCode="AR" term="%22Hoekstra%2C+Pieter+J%2E%22">Hoekstra, Pieter J.</searchLink><br /><searchLink fieldCode="AR" term="%22Plessen%2C+Kerstin+J%2E%22">Plessen, Kerstin J.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Child+%26+Adolescent+Psychiatry%22">European Child & Adolescent Psychiatry</searchLink>. Mar2022, Vol. 31 Issue 3, p425-441. 17p. 1 Chart, 2 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Aripiprazole%22">Aripiprazole</searchLink><br /><searchLink fieldCode="DE" term="%22Tourette+syndrome%22">Tourette syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Tic+disorders%22">Tic disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Dopamine+antagonists%22">Dopamine antagonists</searchLink><br /><searchLink fieldCode="DE" term="%22Risperidone%22">Risperidone</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: In 2011, the European Society for the Study of Tourette Syndrome (ESSTS) published the first European guidelines for Tourette Syndrome (TS). We now present an update of the part on pharmacological treatment, based on a review of new literature with special attention to other evidence-based guidelines, meta-analyses, and randomized double-blinded studies. Moreover, our revision took into consideration results of a recent survey on treatment preferences conducted among ESSTS experts. The first preference should be given to psychoeducation and to behavioral approaches, as it strengthens the patients' self-regulatory control and thus his/her autonomy. Because behavioral approaches are not effective, available, or feasible in all patients, in a substantial number of patients pharmacological treatment is indicated, alone or in combination with behavioral therapy. The largest amount of evidence supports the use of dopamine blocking agents, preferably aripiprazole because of a more favorable profile of adverse events than first- and second-generation antipsychotics. Other agents that can be considered include tiapride, risperidone, and especially in case of co-existing attention deficit hyperactivity disorder (ADHD), clonidine and guanfacine. This view is supported by the results of our survey on medication preference among members of ESSTS, in which aripiprazole was indicated as the drug of first choice both in children and adults. In treatment resistant cases, treatment with agents with either a limited evidence base or risk of extrapyramidal adverse effects might be considered, including pimozide, haloperidol, topiramate, cannabis-based agents, and botulinum toxin injections. Overall, treatment of TS should be individualized, and decisions based on the patient's needs and preferences, presence of co-existing conditions, latest scientific findings as well as on the physician's preferences, experience, and local regulatory requirements. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=155911938
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00787-021-01899-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 17
        StartPage: 425
    Subjects:
      – SubjectFull: Aripiprazole
        Type: general
      – SubjectFull: Tourette syndrome
        Type: general
      – SubjectFull: Tic disorders
        Type: general
      – SubjectFull: Dopamine antagonists
        Type: general
      – SubjectFull: Risperidone
        Type: general
    Titles:
      – TitleFull: European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Roessner, Veit
      – PersonEntity:
          Name:
            NameFull: Eichele, Heike
      – PersonEntity:
          Name:
            NameFull: Stern, Jeremy S.
      – PersonEntity:
          Name:
            NameFull: Skov, Liselotte
      – PersonEntity:
          Name:
            NameFull: Rizzo, Renata
      – PersonEntity:
          Name:
            NameFull: Debes, Nanette Mol
      – PersonEntity:
          Name:
            NameFull: Nagy, Péter
      – PersonEntity:
          Name:
            NameFull: Cavanna, Andrea E.
      – PersonEntity:
          Name:
            NameFull: Termine, Cristiano
      – PersonEntity:
          Name:
            NameFull: Ganos, Christos
      – PersonEntity:
          Name:
            NameFull: Münchau, Alexander
      – PersonEntity:
          Name:
            NameFull: Szejko, Natalia
      – PersonEntity:
          Name:
            NameFull: Cath, Danielle
      – PersonEntity:
          Name:
            NameFull: Müller-Vahl, Kirsten R.
      – PersonEntity:
          Name:
            NameFull: Verdellen, Cara
      – PersonEntity:
          Name:
            NameFull: Hartmann, Andreas
      – PersonEntity:
          Name:
            NameFull: Rothenberger, Aribert
      – PersonEntity:
          Name:
            NameFull: Hoekstra, Pieter J.
      – PersonEntity:
          Name:
            NameFull: Plessen, Kerstin J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: Mar2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 10188827
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: European Child & Adolescent Psychiatry
              Type: main
ResultId 1